{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:25:23Z","timestamp":1780107923557,"version":"3.54.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":759,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:p>Selective oestrogen receptor modulators (SERMs) can build bone in the postmenopausal woman and lower circulating cholesterol. These oestrogen\u2010like properties contrast with the anti\u2010oestrogenic properties observed in the breast where SERMs inhibit the oestrogen\u2010mediated development and growth of ER positive breast cancers. The two clinically useful SERMs, tamoxifen and its chemical cousin raloxifene, are currently used successfully either for the treatment and prevention of breast cancer (tamoxifen) or the treatment and prevention of osteoporosis (raloxifene). However, raloxifene has the beneficial side\u2010effect of breast cancer prevention. These multifunction medicines provide proof of concept that novel molecules can be selectively targeted to diseases mediated by the endocrine system.<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2007) <jats:bold>150<\/jats:bold>, 3\u20134. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0706962\">10.1038\/sj.bjp.0706962<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0706962","type":"journal-article","created":{"date-parts":[[2006,11,20]],"date-time":"2006-11-20T11:05:25Z","timestamp":1164020725000},"page":"3-4","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Beyond raloxifene for the prevention of osteoporosis and breast cancer"],"prefix":"10.1111","volume":"150","author":[{"given":"V C","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg368"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90935-9"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000226637"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.108"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.23.2189"},{"key":"e_1_2_4_7_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/dmd.105.006551","article-title":"Sulfation of raloxifene and 4\u2010hydroxytamoxifen by human cytosolic sulfotransferases","volume":"34","author":"Falany JL","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_4_8_1","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N\u2010nitrosomethylurea\u2010 induced rat mammary carcinoma model","volume":"47","author":"Gottardis MM","year":"1987","journal-title":"Cancer Res"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001883"},{"key":"e_1_2_4_10_1","first-page":"245","article-title":"Biochemical pharmacology of antiestrogen action","volume":"36","author":"Jordan VC","year":"1984","journal-title":"Pharmacol Rev"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357908809082124"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0750305"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806132"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.6.694"},{"key":"e_1_2_4_15_1","first-page":"4177","article-title":"The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture","volume":"50","author":"Lerner LJ","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh319"},{"key":"e_1_2_4_17_1","doi-asserted-by":"crossref","unstructured":"Million Women Study Collaborators(2003).Breast cancer and hormone\u2010replacement therapy in the Million Women Study.Lancet362:419\u2013427.","DOI":"10.1016\/S0140-6736(03)14065-2"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706960"},{"key":"e_1_2_4_19_1","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ajhp\/57.18.1669","article-title":"Raloxifene hydrochloride","volume":"57","author":"Snyder KR","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_4_20_1","first-page":"3270","article-title":"Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268","volume":"8","author":"Suh N","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.23.joc60074"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706962","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0706962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T04:25:55Z","timestamp":1697084755000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0706962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1038\/sj.bjp.0706962"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0706962","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}